General Introduction
Alcohol dependence is a chronic disorder that may have multiple relapses and remissions, increased mortality and low long-term abstinence rates that lead to increased psychosocial losses. Many drugs have been used in the treatment of this disorder such as the anti-craving agents, acamprosate, naltrexone and the aversive agent, disulfiram
[1, 2]. Disulfiram (trade name: Antabuse) has been in use since the early 1940s for the treatment of alcohol dependence and is the first FDA-approved medication for the treatment of this disorder
[3,4,5]. Disulfiram has thus completed almost 60 years of use in alcohol use disorders and has stood the test of time
[6]. A large number of studies have been done on this molecule, ever since some proving its superiority over other drugs while others negating it.
Uses
Disulfiram , is a sulfur- and nitrogen-containing compound with several industrial uses, including applications as a rubber accelerator and vulcanizer, fungicide, and seed disinfectant. It is most commonly known as antabuse, a therapeutic agent for the treatment of alcohol abuse that causes nausea, vomiting, and other adverse effects when ethanol is ingested. Disulfiram is an inhibitor of aldehyde dehydrogenase so that it allows for buildup of the acetaldehyde metabolite of ethanol, causing unpleasant effects that are a deterrent to the ingestion of alcohol. Because of the buildup of acetaldehyde, disulfiram should be given with extreme caution, especially to individuals suffering from liver cirrhosis.
Indications
Disulfiram is used as a second line treatment of alcohol dependence, behind acamprosate and naltrexone
[8]. It is an aid for the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. However, it should be noted that disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic dependence
[5]. Disulfiram should not be taken if alcohol has been consumed in the last 12 hours
[9].
Recently, more and more studies have shown that disulfiram has the potential for the treatment of cancer
[12, 13] and HIV infections
[10, 11]. Disulfiram (DSF) can reactivate latent HIV-1 expression in a primary cell model of virus latency and has the potential to deplete the latent HIV-1 reservoir in patients on combination antiretroviral therapy. DSF can reactivate latent HIV-1 expression via the Akt signaling pathway through depletion of PTEN
[10]. Recent studies have disclosed a surprising, but mechanistically consistent, anticancer activity of disulfiram. Disulfiram has been successfully used to suppress hepatic metastases originating from ocular melanoma
[12]. The anticancer mechanism of disulfiram is through inhibiting the 26S proteasome (The orderly degradation of cellular proteins is critical for normal cell cycling and function, and inhibition of the proteasome pathway results in cell-cycle arrest and apoptosis)
[12-14]. Moreover, disulfiram was also found to have specific activity against zinc fingers and RING-finger ubiquitin E3 ligases that play an important role in cancer development
[12, 13].
Mode of action
Ethanol undergoes metabolism in the liver initially by alcohol dehydrogenase (ADH) forming acetaldehyde; this is removed from the body primarily by oxidation into acetate by acetaldehyde dehydrogenase (ALDH)
[15], which finally enters the citric acid cycle. Disulfiram acts by inhibiting the enzyme ALDH via its metabolite S-methyl N, N-diethyl-dithio-carbamate-sulphoxide
[16], leading to accumulation of acetaldehyde in blood. This gives rise to various manifestations of disulfiram-alcohol reaction (DER)
[17]. Since the inhibition of ALDH by disulfiram is irreversible, the DER will get terminated only after production of new ALDH oncedisulfiram is stopped. The new ALDH takes about a week’s time to be produced. Hence patients should be advised to take alcohol only after 2 weeks of stopping disulfiram
[18]. In addition to this, disulfiram also acts on the dopaminergic system, both disulfiram and its metabolite carbon disulfide leading to inhibition of dopamine beta-hydroxylase (DBH) that leads to increase in the levels of dopamine. This may give rise to several neuropsychiatric manifestations such as delirium, paranoia, impairment of memory, ataxia, dysarthria and frontal lobe release signs
[19]. Besides this action, disulfiram is also known to inhibit dopamine beta-hydroxylase leading to an increase in dopamine concentrations but decreased norepinephrine in the brain
[20]. This may suggest an anti-craving role of disulfiram in alcohol dependence
[21].
Adverse reactions
In severe cases, hepatitis such as both cholestatic and fulminant hepatitis, as well as hepatic failure resulting in transplantation or death, could occur upon treatment of disulfiram
[5]. In a small number of patients, side effects include a transient mild drowsiness, fatigability, impotence, headache, acneform eruptions, allergic dermatitis, or a metallic or garlic-like aftertaste during the first two weeks of therapy. These reactions often disappear spontaneously with the continuation of therapy, or with reduced dosage. High dosage, combined toxicity (with metronidazole or isoniazid), or to the unmasking of underlying psychoses can cause psychotic reactions
[5].
Warning and precaution
The following tips should be pay attention during administration of disulfiram
[9].
Disulfiram is not allowed if the patients have consumed alcohol within the past 12 hours. Do not drink alcohol while taking disulfiram and for up to 14 days after stop taking disulfiram.
It is not known whether disulfiram will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medicine. It is not known whether disulfiram passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine. People less than 18 years old should also disabled.
Disulfiram should not be used in the following cases:
Allergic people; those who have recently taken metronidazole (Flagyl) or paraldehyde; or have consumed any foods or products that contain alcohol;
People of the following cases should consult the doctors:
Liver or kidney disease; heart disease, high blood pressure, history of heart attack or stroke;
Underactive thyroid; diabetes; seizures or epilepsy; head injury or brain damage; a history of mental illness or psychosis; an allergy to rubber; or taking phenytoin (Dilantin), tuberculosis medicine, or a blood thinner (warfarin, Coumadin, Jantoven).
Mechanism of action
Disulfiram is an oral drug used for treating alcoholism. Alcohol is converted in the body into acetaldehyde by an enzyme called alcohol dehydrogenase. Another enzyme called acetaldehyde dehydrogenase then converts acetaldehyde into acetic acid. Disulfiram prevents acetaldehyde dehydrogenase from converting acetaldehyde into acetic acid, leading to a buildup of acetaldehyde levels in the blood.
Pharmacodynamics
Disulfiram irreversibly inhibits aldehyde dehydrogenase, which prevents the oxidation of alcohol after the acetaldehyde stage. It interacts with ingested alcohol to produce acetaldehyde levels five to ten times higher than are produced by normal alcohol metabolism. Excess acetaldehyde produces a highly unpleasant reaction (nausea and vomiting) to even a small quantity of alcohol. Tolerance to disulfiram doesn’t occur; rather, sensitivity to alcohol increases with longer duration of therapy.
Interactions
Some individuals should never take disulfiram, and others should use extra caution when taking the drug. Do not take disulfiram if you have a nickel allergy, a sulfur allergy or a hypersensitivity to disulfiram or other derivatives of thiuram, which are commonly found in rubber.
References
- Bouza, C., Angeles, M., Muñoz, A., & Amate, J. M. (2015). Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction, 99(7), 811-828.
- Laaksonen, E., Koskijännes, A., Salaspuro, M., Ahtinen, H., & Alho, H. (2008). A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol & Alcoholism, 43(1), 53.
- Petrakis, I.L., Nich, C. and Ralevski, E. (2006) Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effective-ness of naltrexone and disulfiram. Schizophrenia Bulletin, 32, 644-654.
- De Sousa, A. (2010) The pharmacotherapy of alcohol dependence: A state of the art review. Mens Sana Monographs, 8, 69-82.
- https://www.rxlist.com/antabuse-drug.htm
- Krampe, H., & Ehrenreich, H. (2010). Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Current Pharmaceutical Design, 16(19), (60 years)
- Johansson, B. (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatrica Scandanavica, 362, 15-26.
- https://www.ncbi.nlm.nih.gov/books/NBK459340/
- https://www.drugs.com/pro/disulfiram.html
- Doyon, G., Zerbato, J., Mellors, J. W., & Sluiscremer, N. (2013). Disulfiram reactivates latent hiv-1 expression through depletion of the phosphatase and tensin homolog. Aids, 27(2), F7-F11.
- Rasmussen, TA; Lewin, SR (July 2016). "Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?". Current Opinion in HIV and AIDS.
- Cvek, B., & Dvorak, Z. (2008). The value of proteasome inhibition in cancer: can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?. Drug Discovery Today, 13(15), 716-722.
- Kona, F. R., Buac, D., & A, M. B. (2011). Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies. Current Cancer Drug Targets, 11(3).
- Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005). Proteasome inhibition as a novel therapeutic target in human cancer. Journal of Clinical Oncology, 23(3), 630-639.
- Deitrich, R.A., Petersen, D. and Vasiliou, V. (2007) Removal of acetaldehyde from the body. Novartis Foundation Symposia, 285, 23-40.
- Pike, M.G., Mays, D.C., Macomber, D.W. and Lipsky, J.J. (2001) Metabolism of a disulfiram metabolite S-methyl N,N-diethyldithiocarbamate by flavinmonooxygenase in human renal microsomes. Drug Metabolism & Disposition, 29, 127-132.
- Larsen, V. (1948) The effects on experimental animals of antabuse (tetraethylthiuram disulfide) in combination with alcohol. Acta Pharmacologica Toxicology, 4, 321-332.
- Krampe, H. and Ehrenreich, H. (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Current Pharmaceutical Design, 16, 2076-2090.
- Fuller, R.K. and Gordis, E. (2004) Does disulfiram have a role in alcoholism treatment today? Addiction, 99, 21-24.
- Vaccari, A., Saba, P.L., Ruiu, S., Collu, M. and Devoto, P. (1996) Disulfiram and diethyldithiocarbamate intoxica-tion affects the storage and release of striatal dopamine. Toxicology & Applied Pharmacology, 139, 102-108.
- Muller, C.A. and Banas, R. (2011) Disulfiram: An anti-craving substance? American Journal of Psychiatry, 168, 98.
Description
Disulfiram was first synthesized in the 1800s to improve the
manufacturing process of rubber. A physician working in
a rubber factory plant first observed in 1937 that factory
workers who were exposed to disulfiram were intolerant to
ethanol. In the 1940s, two scientists rediscovered the disulfiram–
ethanol effects while researching antiparasitic therapies.
This finding eventually led to the approval of the medication to
be used as an ethanol deterrent by the Food and Drug
Administration in 1951.
Chemical Properties
yellow-white crystals or grey powder
Originator
Esperal,Millot Solac,France,1950
Uses
Alcohol deterrent;Dopamine beta-hydroxylase inhibitor;For the treatment and management of chronic alcoholism.
Uses
It is used as rubber accelerator; vulcanizer; seed disinfectant; fungicide; alcohol deterrent.
Uses
Disulfiram is a copper and zinc chelator and an irreversible inhibitor of aldehyde dehydrogenase (IC50 = 0.1 mM) that has been indicated for the treatment of alcohol dependence. It also inhibits the copper-dependent enzyme dopamine β-hydroxylase, which prevents the breakdown of dopamine and has been considered as a treatment for cocaine dependence. When in complex with copper, disulfiram has been shown to inhibit purified 20S proteasome (IC50 = 7.5 μM) and 26S proteasome (IC50 = 20 μM) from MDA-MB-0231 breast cancer cells. Because disulfiram targets the ubiquitin-proteasome pathway, it has been investigated as an anti-cancer agent. Furthermore, at 250 nM it has been shown to induce reactive oxygen species, to activate JNK and p38 pathways, and to inhibit NF-κB activity, which suppresses self-renewal in cancer stem cells.
Definition
ChEBI: An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.
Manufacturing Process
Disulfiram may be made by the reaction of diethyl amine with carbon disulfide
in the presence of sodium hydroxide. The (C2H5)2NCSSNa intermediate is
oxidatively coupled using hydrogen peroxide to give disulfiram.
brand name
Antabuse (Odyssey)
.
Therapeutic Function
Alcohol deterrent
General Description
Odorless or almost odorless white or almost white to tan powder. Unpleasant taste with metallic or garlic aftertaste. pH of a solution obtained by shaking 1 g with 30 mL of water is 6 to 8.
Air & Water Reactions
Insoluble in water.
Reactivity Profile
Disulfiram is sensitive to light. Disulfiram is incompatible with strong acids, strong oxidizers and nitrosating agents (e.g. N-Nitrosodiphenylamine). .
Hazard
Toxic symptoms when ingested with alcohol;
animal teratogen. Vasodilation and nausea.
Questionable carcinogen.
Health Hazard
Disulfiram affects the central
nervous system, thyroid, and skin; in combination
with alcohol it causes an “Antabusealcohol”
syndrome.
Small doses of disulfiram reportedly can
cause effects on thyroid iodine uptake and
thyroid gland hypertrophy. It may also
produce dermatitis and acneform rashes.
Fire Hazard
Flash point data for Disulfiram are not available; however, Disulfiram is probably combustible.
Flammability and Explosibility
Not classified
Biological Activity
Inhibitor of aldehyde dehydrogenase that displays antialcoholism activity. Shown to reversibly stimulated Ca 2+ -ATPase activity and inhibit V-ATPase (EC 50 = 26 μ M). Also inhibits expression of MMP-2 and MMP-9 and displays anti-invasive activity.
Contact allergens
TETD is a rubber accelerator of the thiuram group, contained in “thiuram mix.” It can cross-react with other thiurams, especially TMTD. TETD is used to aid those trying to break their dependence on alcohol. The disulfiram-alcohol reaction is not allergic but due to the accumulation of toxic levels of acetaldehyde. The implanted drug can, however, lead to local or generalized dermatitis, for example ingested disulfiram, mainly in previously rubber-sensitized patients. As an adjunctive treatment of alcoholism, it caused occupational contact dermatitis in a nurse.
Clinical Use
Adjunct in the treatment of chronic alcohol dependence
Safety Profile
A human poison by
ingestion. An experimental poison by
intraperitoneal route. Toxic symptoms when
accompanied by ingestion of alcohol.
Human systemic effects by ingestion:
jaundtce, joint changes. An experimental
teratogen. Other experimental reproductive
effects. Questionable carcinogen with
experimental neoplastigenic data. See also
THIRAM.
Synthesis
Disulfiram solid dispersions were prepared with polyvinylpyrrolidone (PVP) as carrier by either an evaporation method or a spray-drying method[1].
Potential Exposure
AgriculturalChemical; Drug, Tumorigen, Mutagen; ReproductiveEffector; Human Data; Hormone, Primary Irritant. Somethiurams have been used as rubber components. Disulfiramis used as an accelerator in compounding natural, styrenebutadiene, and Neoprene rubbers as a rubber acceleratorand vulcanizer; as a seed disinfectant and fungicide; in therapy; as an alcohol deterrent; in adhesives.
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: risk of severe disulfiram reaction.
Anticoagulants: enhanced anticoagulant effect with
coumarins.
Antiepileptics: inhibition of metabolism of
fosphenytoin and phenytoin (increased risk of
toxicity).
Paraldehyde: increased risk of toxicity with
paraldehyde.
First aid
If this chemical gets into the eyes, remove anycontact lenses at once and irrigate immediately for at least15 min, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts theskin, remove contaminated clothing and wash immediatelywith soap and water. Seek medical attention immediately. Ifthis chemical has been inhaled, remove from exposure,begin rescue breathing (using universal precautions, including resuscitation mask) if breathing has stopped and CPR ifheart action has stopped. Transfer promptly to a medicalfacility. When this chemical has been swallowed, get medical attention. Give large quantities of water and inducevomiting. Do not make an unconscious person vomit.Note: For alcohol/disulfiram or ethylene dibromide/disulfiram reaction, remove the person from exposure. Begin rescue breathing (using universal precautions, includingresuscitation mask) if breathing has stopped and CPR ifheart action has stopped. Transfer promptly to a medicalfacility.
Carcinogenicity
In a lifetime carcinogenicity bioassay,
disulfiram was not carcinogenic in either rats
or mice when fed in the diet. The highest
doses were 600 ppm in rats and 2000ppm in
mice.
Increased fetal resorptions, but no teratogenic
effects, were seen in rats exposed at
100mg/kg/day from day 3 of gestation. A weak
genotoxic response was observed in mice
treated in vivo as evidenced by an increase in
sister chromatid exchanges in bone marrow
and spermatogonial cells.9
The 2003 ACGIH threshold limit valuetime-
weighted average (TLV-TWA) is
2mg/m3.
Metabolism
Disulfiram is rapidly reduced to diethyldithiocarbamate,
mainly by the glutathione reductase system in
erythrocytes; reduction may also occur in the liver.
Diethyldithiocarbamate is metabolised in the liver to its
glucuronide and methyl ester and to diethylamine, carbon
disulfide, and sulfate ions. Metabolites are excreted mainly
in the urine; carbon disulfide is exhaled in the breath.
Shipping
Toxic solids, flammable, organic, n.o.s. requiresa shipping label of “POISONOUS/TOXIC MATERIALS.”They fall into Hazard Class 6.1.
Toxicity evaluation
Disulfiram has multiple mechanisms of toxicity. Its most welldefined
action is inhibition of aldehyde dehydrogenase, which
thereby diminishes the breakdown of acetaldehyde. Accumulation
of carbon disulfide, a disulfiram metabolite, as well as
inhibition of dopamine-b-hydroxylase has also been associated
with its toxicity in particular related to use for cocaine
dependence.
References
[1]NABEKURA, T., ITO, Y., CAI, H., TERAO, M., & HORI, R. (2000). Preparation and in Vivo Ocular Absorption Studies of Disulfiram Solid Dispersion. Biological and Pharmaceutical Bulletin, 23(5), 616–620.
https://doi.org/10.1248/bpb.23.616
